Published by Josh White on 20th October 2025
(Sharecast News) - Avacta Group announced on Monday that it has raised £16m through an oversubscribed equity placing to accelerate development of its oncology pipeline, as new clinical data presented at the European Society for Medical Oncology (ESMO) demonstrated strong efficacy and safety for its lead program, faridoxorubicin (AVA6000).